Cadrenal (CVKD) CEO files Form 4; sells 2,444 shares

Cadrenal Therapeutics (CVKD): CEO/Chairman Quang Pham reported open‑market sales under a Rule 10b5‑1 plan.

(Neutral)

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Cadrenal Therapeutics (CVKD): CEO/Chairman Quang Pham reported open‑market sales under a Rule 10b5‑1 plan. On 10/24/2025, he sold 1,129 shares of common stock at a weighted average price of $14.03, with trades ranging from $13.99 to $14.10. On 10/27/2025, he sold 1,315 shares at a weighted average price of $13.99, with trades ranging from $13.99 to $14.00. The trading arrangement was adopted on May 9, 2025.

Following these transactions, direct beneficial ownership was 197,404 shares after the first sale and 196,089 shares after the second. He also holds 200,000 shares indirectly through The PVBQ Living Trust, for which he serves as trustee with sole voting and disposition power.

Insider Trade Summary

Net Seller: 2,444 shares

Net Sell 3 txns

Insider Pham Quang X

Role CEO and Chairman

Sold 2,444 shs ($34K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,315	$13.99	$18K
Sale	Common Stock	1,129	$14.03	$16K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 196,089 shares (Direct); Common Stock — 200,000 shares (Indirect, The PVBQ Living Trust)

Footnotes (4)

F1. Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on May 9, 2025.
F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.99 through $14.10. The Reporting Person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.99 through $14.00. The Reporting Person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4. Quang Pham is the Trustee of The PVBQ Living Trust and has sole voting and disposition power with respect to the shares owned by The PVBQ Trust, of which Mr. Pham's child is the sole beneficiary.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CVKD’s CEO report on the latest Form 4?

Open‑market sales of common stock executed under a Rule 10b5‑1 trading arrangement adopted on May 9, 2025.

How many CVKD shares were sold and on which dates?

1,129 shares on 10/24/2025 and 1,315 shares on 10/27/2025.

What were the sale prices for the CVKD transactions?

Weighted averages of $14.03 (range $13.99–$14.10) and $13.99 (range $13.99–$14.00).

How many CVKD shares does the reporting person own directly after the sales?

197,404 shares after the 10/24/2025 sale and 196,089 shares after the 10/27/2025 sale.

Does the reporting person have indirect ownership in CVKD?

Yes. 200,000 shares are held indirectly through The PVBQ Living Trust, for which he is trustee.

What is the reporting person’s role at CVKD?

Director, CEO and Chairman, and a 10% owner.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 10/28/2025 - 05:00 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pham Quang X

(Last)

(First)

(Middle)

C/O CADRENAL THERAPEUTICS, INC.,

822 A1A NORTH, SUITE 306

(Street)

PONTE VEDRA,

32082

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Cadrenal Therapeutics, Inc. [ CVKD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and Chairman

3. Date of Earliest Transaction (Month/Day/Year)
10/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/24/2025		S		1,129⁽¹⁾	D	$14.03⁽²⁾	197,404	D
Common Stock	10/27/2025		S		1,315⁽¹⁾	D	$13.99⁽³⁾	196,089	D
Common Stock								200,000	I	The PVBQ Living Trust⁽⁴⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on May 9, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.99 through $14.10. The Reporting Person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.99 through $14.00. The Reporting Person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

4. Quang Pham is the Trustee of The PVBQ Living Trust and has sole voting and disposition power with respect to the shares owned by The PVBQ Trust, of which Mr. Pham's child is the sole beneficiary.

	/s/ Matthew K. Szot, Attorney-in-fact	10/28/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR